SIGA Technologies

SIGA Technologies FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of SIGA Technologies (SIGA) as of Nov 2, 2026 is 185.05 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 82.28 % — a change of 124.91% (higher).

FCF Conversion

185.05 %

YoY

124.91%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of SIGA Technologies is 2025 185.05 % . FCF Conversion Rate (FCF/EBITDA) of SIGA Technologies was 2024 82.28 % . It decreases by 124.91% higher compared to the previous year.

The SIGA Technologies FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
16.30 USD
Jan 1, 2019
251.80 USD
Jan 1, 2020
126.91 USD
Jan 1, 2021
16.48 USD
Jan 1, 2022
122.73 USD
Jan 1, 2023
139.24 USD
Jan 1, 2024
82.28 USD
Jan 1, 2025
185.05 USD
The SIGA Technologies FCF Conversion history
YEARFCF ConversionYoY
185.05 %+124.91%
82.28 %-40.91%
139.24 %+13.45%
122.73 %+644.81%
16.48 %-87.02%
126.91 %-49.60%
251.80 %+1,444.48%
16.30 %-28.47%
22.79 %-92.17%
291.24 %-1,144.47%
-27.88 %+423.17%
-5.33 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SIGA Technologies Stock analysis

What does SIGA Technologies do? SIGA Technologies Inc was founded in 1995 and is headquartered in New York, USA. The company specializes in developing, producing, and distributing medical solutions for viral diseases, particularly for the treatment of smallpox. SIGA Technologies' business model is based on the development of antiviral drugs and vaccines that help in the treatment and prevention of infectious diseases. The company has a wide range of technologies and knowledge to develop innovative products. The focus is on researching viral diseases to find new treatment options and make them accessible. The company has several divisions that focus on different areas of virus infection treatment. The first division focuses on the treatment of smallpox. The company has produced the first approved medication for smallpox, Tecovirimat. Tecovirimat is an antiviral drug used for the treatment of smallpox. It is the only medication approved by the US Food and Drug Administration (FDA) for the treatment of smallpox. Another division of SIGA Technologies is dedicated to the development of antiviral agents that can control the spread of diseases such as Ebola, Lassa fever, and other viral diseases. The company has several promising drugs in the pipeline to meet the global demand for antiviral medications. SIGA Technologies also has innovative products in the diagnostics division. The company has developed a platform technology that allows for rapid and accurate diagnosis of virus infections. The platform, called AmpliPhi is Thermal Unwinding (AITU) technology, enables the diagnosis of a variety of virus infections and allows for targeted treatment to be initiated quickly. These tests can be performed both in laboratories and on-site, making them particularly valuable for use in medical facilities in rural areas or highly affected areas. Overall, SIGA Technologies has a broad portfolio of products and solutions for the treatment and prevention of virus infections. The company has an experienced and knowledgeable team of scientists and experts in this field, continuously driving new developments. SIGA Technologies is committed to making a contribution to improving global health and to having positive impacts on public health through its products and services. SIGA Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SIGA Technologies stock

FCF Conversion Rate (FCF/EBITDA) of SIGA Technologies is 185.05 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of SIGA Technologies changed from 82.28 % to 185.05 %, representing a 124.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) SIGA Technologies since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s SIGA Technologies with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — SIGA Technologies

All Key Metrics — SIGA Technologies